These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31106345)

  • 21. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
    Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of long-term treatment with linezolid in cystic fibrosis: case report.
    Spicuzza L; Sciuto C; La Rosa M
    J Chemother; 2008 Jun; 20(3):399-401. PubMed ID: 18606604
    [No Abstract]   [Full Text] [Related]  

  • 23.
    Pfaller MA; Sader HS; Rhomberg PR; Flamm RK; Mendes RE
    Microb Drug Resist; 2019; 25(6):938-943. PubMed ID: 30694735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA.
    McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL
    BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Listeria monocytogenes meningitis and multiple brain abscesses in an immunocompetent host. Favorable response to combination linezolid-meropenem treatment.
    Manfredi R; Sabbatani S; Marinacci G; Salizzoni E; Chiodo F
    J Chemother; 2006 Jun; 18(3):331-3. PubMed ID: 17129848
    [No Abstract]   [Full Text] [Related]  

  • 26. Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia.
    Grau S; Morales-Molina JA; Mateu-de Antonio J; Marín-Casino M; Alvarez-Lerma F
    J Antimicrob Chemother; 2005 Aug; 56(2):440-1. PubMed ID: 15956097
    [No Abstract]   [Full Text] [Related]  

  • 27. Linezolid, quinupristin/dalfopristin, and daptomycin in dermatology.
    Wesson KM; Lerner DS; Silverberg NB; Weinberg JM
    Clin Dermatol; 2003; 21(1):64-70. PubMed ID: 12609590
    [No Abstract]   [Full Text] [Related]  

  • 28. Reduction in Tedizolid Plasma Exposure among End-Stage Renal Disease Patients Undergoing Dialysis Is Explained by Variations in Ideal Body Weight.
    Flanagan S; Prokocimer P
    Antimicrob Agents Chemother; 2016 May; 60(5):3246-7. PubMed ID: 26926636
    [No Abstract]   [Full Text] [Related]  

  • 29. Hypertensive crisis following the administration of tedizolid: possible serotonin syndrome.
    de Castro Julve M; Miralles Albors P; Ortonobes Roig S; Vives R; Falgueras L; Gómez-Valent M
    Eur J Hosp Pharm; 2020 Jan; 27(1):52-54. PubMed ID: 32064090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis.
    Park IN; Hong SB; Oh YM; Kim MN; Lim CM; Lee SD; Koh Y; Kim WS; Kim DS; Kim WD; Shim TS
    J Antimicrob Chemother; 2006 Sep; 58(3):701-4. PubMed ID: 16857689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective.
    Udwadia ZF; Sen T; Moharil G
    Eur Respir J; 2010 Apr; 35(4):936-8; author reply 938-40. PubMed ID: 20356997
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparative Assessment of Tedizolid Pharmacokinetics and Tissue Penetration between Diabetic Patients with Wound Infections and Healthy Volunteers via
    Stainton SM; Monogue ML; Baummer-Carr A; Shepard AK; Nugent JF; Kuti JL; Nicolau DP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis.
    Sotgiu G; Lange C; Richardson MD; Matteelli A; Centis R; Eker B; Guenther G; Spanevello A; Migliori GB;
    J Antimicrob Chemother; 2009 Oct; 64(4):879-83; author reply 883-4. PubMed ID: 19651787
    [No Abstract]   [Full Text] [Related]  

  • 34. [The significance of antibiotic-hypersensitivity syndrome].
    Urbina O; Ferrández O; Espona M; Grau S
    Enferm Infecc Microbiol Clin; 2011; 29(7):558-9. PubMed ID: 21570160
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
    Douros A; Grabowski K; Stahlmann R
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Painful polyneuropathy secondary to prolonged treatment with linezolid: presentation of a case.
    Gil Villar MP; García Arguedas C; Santos Lasaosa S; Cía Blasco P
    Neurologia; 2012 Sep; 27(7):443-5. PubMed ID: 22217521
    [No Abstract]   [Full Text] [Related]  

  • 37. [Our experience with linesolid usage in newborn children].
    Atanasova V; Slavkova N; Rosmanova R
    Akush Ginekol (Sofiia); 2007; 46 Suppl 1():60-2. PubMed ID: 18173016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lactic acidosis and linezolid-induced pancytopaenia.
    Carbajo T; Fenollosa M; Pons R; Calvo C
    Nefrologia; 2011; 31(1):107-8. PubMed ID: 21270922
    [No Abstract]   [Full Text] [Related]  

  • 39. Long-term Use of Tedizolid as Suppressive Therapy for Recurrent Methicillin-Resistant Staphylococcus aureus Graft Infection.
    Nigo M; Luce AM; Arias CA
    Clin Infect Dis; 2018 Jun; 66(12):1975-1976. PubMed ID: 29370350
    [No Abstract]   [Full Text] [Related]  

  • 40. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17).
    Carvalhaes CG; Sader HS; Flamm RK; Mendes RE
    J Antimicrob Chemother; 2019 Jul; 74(7):1928-1933. PubMed ID: 30932152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.